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Abstract
Background: To clarify the feasibility and efficacy of chemoradiotherapy (CRT) in elderly (age≥65 years) patients
with locoregionally advanced nasopharyngeal carcinoma (NPC).
Methods: From January 2000 to December 2006, 101 newly diagnosed elderly non-metastatic NPC patients
(age≥65 years) who received cisplatin 3-weekly or weekly concurrent CRT with/without sequential chemotherapy
were recruited. Each patient from the CRT group was matched to another patient treated with radiotherapy (RT)
alone based on age, gender, pathological type, performance status, overall stage, stage method, Adult Comorbidity
Evaluation-27 (ACE-27) score and RT technique, from the same institute and time period. We also recruited 101
young patients (age<65 years) as the referent group, which had been matched to the CRT group based on patient
characteristics and treatment parameters. Treatment tolerability and toxicity were clarified, and treatment outcomes
were calculated and compared among groups.
Results: CRT was feasible in elderly NPC patients, while a concurrent regimen of weekly cisplatin was more
tolerable. Grade≥3 acute toxicity in CRT group was similar with referent group, although it was significantly higher
than the RT alone group (65.3% vs. 43.6%, P=0.002). Furthermore, patients with ACE-27 score≥2 in the CRT group
had significantly higher severe acute toxicity and dose reduction. Survival was poorer in elderly patients than the
referent group. Compared to RT alone, CRT significantly improved the 5-year overall survival (OS: 54.6% vs. 39.3%,
P=0.009), cancer-specific survival (CSS: 56.6% vs. 42.7%, P=0.022), disease-free survival (DFS: 51.6% vs. 30.2%, P=0.028)
and locoregional relapse-free survival (LRRFS: 78.4% vs. 52.2%, P=0.003), but not distant metastasis-free survival
(DMFS: 69.6% vs. 63.6%, P=0.669). However, CRT did not significantly improve 5-year OS (43.6% vs. 27.3%, P=0.893)
or CSS (43.6% vs. 34.1%, P=0.971) in elderly NPC patients with ACE-27 score≥2.
Conclusions: CRT is feasible and effective in elderly patients with locoregionally advanced NPC without severe
comorbidities. CRT should be used under serious consideration and be further tested in elderly patients with severe
comorbidities. As such, it is essential to perform a comprehensive evaluation of pretreatment comorbidity status for
all elderly NPC patients.
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Background
Nasopharyngeal carcinoma (NPC) differs from other
head and neck cancers because of its unique characteris-
tics with regard to epidemiology, pathological types and
therapeutic managements [1]. NPC is prevalent in
southern China, Singapore and Malaysia, although it is
rare in the United States and Western Europe. The
Intergroup Study 0099 and several other prospective
randomized trials that were conducted in endemic areas
have demonstrated that, compared to radiotherapy (RT)
alone, concurrent chemoradiotherapy (CRT) with/with-
out adjuvant chemotherapy could significantly improve
survival of locoregionally advanced NPC, although with
higher rates of acute toxicities [2-7]. Since then, concur-
rent CRT with/without adjuvant chemotherapy has be-
come the standard treatment modality for these patients.
However, elderly NPC patients only comprise a small
part in these clinical trials because of restrictive selection
criteria. In addition, in real clinical practice, co-existing
ailments and decreasing organ function are common
among the elderly. As such, the safety and efficacy of
standard treatment modalities for the elderly population
is still unknown. A previous systemic review showed that
patients with comorbidities had a higher rate of
chemotherapy-induced grade 3 to 4 toxicity [8]. When
faced with the choice between benefits and toxicities
caused by CRT, many oncologists prefer RT alone, which
was already demonstrated to be tolerable in elderly pa-
tients with head and neck cancers and NPC [9-11], how-
ever, this conservative treatment selection may prevent
some elderly patients from longer survival. Since the
safety and outcome of CRT in elderly NPC patients are
still not clear, the blind selection of either RT alone or
CRT is inappropriate. Therefore, we conducted a
matched cohort analysis to analyze the feasibility and




This retrospective matched cohort analysis recruited el-
derly patients (aged≥65 years) with locoregionally ad-
vanced NPC treated by CRT or RT alone. The study was
approved by the institutional reviewed board at Sun
Yat-sen University Cancer Center. Selection criteria for
CRT cases included the following patients: the elderly
(age≥65 years); those with newly diagnosed NPC without
metastasis; those with stage III-IVb disease (the 7th
American Joint Committee on Cancer/Union for Inter-
national Cancer Control (AJCC/UICC) staging system)
([12], Additional file 1), where patients assessed with a
former staging system were re-staged according to
the 7th AJCC/UICC staging system; those who finished
radical RT in the end; those treated with concurrent
chemotherapy using cisplatin with/without sequential
chemotherapy (e.g., neoadjuvant and/or adjuvant che-
motherapy); and those without history of previous
chemotherapy or RT.
From January 2000 to December 2006, 11,173 newly di-
agnosed non-metastatic NPC patients were registered at
Sun Yat-sen University Cancer Center, of them 804 (7.2%)
patients were 65 years old or over. Figure 1 shows the
flowchart of patients. Finally, 101 patients who met the
above criteria were included in our CRT group. Each pa-
tient in the CRT group was matched with another patient
from a group of 311 patients treated with RT alone at the
same institution and during the same period. The matched
prognostic factors included the following: age (65–69 years
and ≥70 years), gender (male and female), pathological type
(WHO types II-III and WHO type I), performance status
(ECOG scores of 0–1 and 2), overall stage (stage III and
IVa-b), stage method (CT and MRI), Adult Co-morbidity
Evaluation-27 (ACE-27) ([13]; Additional file 2) scores
(0–1 and 2–3) and RT techniques (2D conventional RT
and 3D conformal RT or intensity-modulated radiotherapy
(IMRT)). When an exact match was not available, a patient
with more favorable characteristics from the RT alone
group was selected to prevent results from being biased in
favor of the CRT group. We also recruited 101 young pa-
tients (age<65 years) with locoregionally advanced NPC at
the same institute and during the same time period as the
Figure 1 Flowchart of patients. NPC: Nasopharyngeal carcinoma;
RT: Radiotherapy; CRT: Chemoradiotherapy; CT: Chemotherapy.
*Other drugs included carboplatin (N=43), nedaplatin (N=28),
paclitaxel (N=9), docetaxel (N=8), and Xeloda (N=7).
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referent group, and patient characteristics and treatment
parameters were matched to the CRT group.
Table 1 summarizes the patient characteristics of the
three groups. Elderly patients from the CRT and RT
alone group were completely matched for age, gender,
pathological type, ACE-27 score, and stage method. The
percentages of patients matched for performance status,
overall stage and RT technique were 99.0%, 97.0% and
99.0%, respectively. Except for ACE-27 score (98.0%)
and RT technique (98.0%), patient characteristics were
completely matched between the CRT and referent
group.
Pretreatment assessment
All patients were evaluated with a physical examination,
complete blood count, liver and renal biochemistries,
fiberoptic endoscopy of the nasopharynx, chest radio-
graph, abdominal ultrasonography, magnetic resonance
imaging (MRI) or computed tomography (CT) of the
nasopharynx and neck region, and bone scan by emis-
sion computed tomography.
We re-staged all patients using the 7th AJCC/UICC
staging system according to data from the clinical exam-
inations and imaging.
ACE-27 was used as uniform criteria to evaluate comor-
bidity status. We reviewed individual medical records of
each patient to perform the ACE-27 assessments. Comor-
bid conditions and ailments were categorized as none
(score 0), mild (score 1), moderate (score 2), or severe
(score 3), according to the degree of organ decompensa-
tion. Following principles described in the Comorbidity
Coding Book [Additional file 3], those comorbidities lac-
king specific information were categorized as mild. These
scores were then used to designate an overall comorbidity
ranking according to the highest ranked ailment. Patients
with more than two moderate ailments in different organ
systems were considered as severe. Table 2 shows the de-
tails of comorbidity in two elderly groups. The most fre-
quently affected systems were cardiovascular (17.8%), and
then the gastrointestinal (11.9%) and endocrine systems
(6.4%). Of note, 9 (4.5%) patients bore diseases from two
or more organ systems.
RT
All patients received radical radiotherapy with a 6 MV
photon beam. In total, 92.6% (187/202) of elderly patients
received conventional 2D RT, while only 1.0% (2/202) and
6.4% (13/202) received 3D conformal RT and IMRT, res-
pectively. Patients were treated with conventional 2D RT
using a uniform RT protocol based on the treatment poli-
cy for NPC at our cancer center [14].
RT was given five times a week at 2 Gy/day (2D conven-
tional and 3D conformal RT) or 2.12-2.19 Gy/day (IMRT).
The cumulative dose was 68–72 Gy to the primary tumor
site, 60–62 Gy to the involved areas of the neck, and
50Gy to uninvolved neck areas. The median cumulative
dose of the primary site and neck area were 70Gy and
60Gy in RT alone group, 70 Gy and 62Gy in CRT group,
and 70Gy and 60Gy in the reference group, respectively.
Chemotherapy
Patients from the CRT group received concurrent che-
motherapy with cisplatin with/without sequential che-
motherapy (neoadjuvant and or adjuvant). Cisplatin was
administered at 80 mg/m2 3-weekly or at 40 mg/m2 weekly.
Selection of sequential chemotherapy and concurrent reg-
imens were under consideration of individual doctor. Dose
modification was performed, if necessary, at the discretion
of the doctors.
Chemotherapy was not given in some patients because
of rejected by patients and family, age over 75 years, par-
ticipation in clinical trial, and presence of other medical
conditions that were contra-indicative.
Patient evaluation and follow-up
Patients were assessed at the time of treatment comple-
tion, at least once every three months over the next
three years and at least once every six months thereafter.
The patient evaluation included a clinical examination,
nasopharyngeal endoscopy, CT or MRI of the nasopha-
rynx and the neck area, chest radiograph and abdominal
ultrasonography.
Statistical methods
The following endpoints were examined: 5-year overall
survival (OS), cancer-specific survival (CSS), disease-free
survival (DFS), locoregional relapse-free survival (LRRFS),
and distant metastasis-free survival (DMFS). All endpoints
were calculated from the date of treatment commence-
ment to the date of the observed endpoints or to the date
of the last follow-up.
Category variables were compared using Pearson χ2 test.
Survival endpoints were analyzed using the Kaplan-Meier
product-limit method [15]. The log-rank test was used to
analyze the statistical significance of differences among
the survival curves [16]. Treatment toxicity rates between
the two groups were compared using the chi-squared test
(or Fisher’s exact test, if indicated).
Analyses were performed using the SPSS statistical soft-
ware package, version 16.0 (SPSS, Chicago, IL, USA). All
statistical tests were two-tailed, and P-values < .05 were
considered to be statistically significant.
Results
Treatment compliance
Only 7 elderly patients (3.5%) experienced RT interrup-
tion, among whom 4 and 3 patients were from the CRT
and RT groups, respectively. However, the difference
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Table 1 Patients’ characteristics
RT group (%) CRT group (%) Referent group (%)
N=101 N=101 N=101
Age
≥65, <70 78 (77.2) 78 (77.2)
≥70 23 (22.8) 23 (22.8)
Median 68 69 45
Range 65-80 65-77 18-65
Gender
Male 81 (80.2) 81 (80.2) 81 (80.2)
Female 20 (19.8) 20 (19.8) 20 (19.8)
Histology
WHO type I 1 (1.0) 1 (1.0) 1 (1.0)
WHO type II 10 (9.9) 14 (13.9) 12 (11.9)
WHO type III 90 (89.1) 86 (85.1) 88 (87.1)
PS score (ECOG)
0 0 (0) 1 (1.0) 1 (1.0)
1 101 (100) 99 (98.0) 99 (98.0)
2 0 (0) 1 (1.0) 1 (1.0)
ACE-27 score
0 64 (63.4) 67 (66.3) 70 (69.3)
1 26 (25.7) 23 (22.8) 22 (21.8)
2 10 (9.9) 10 (9.9) 8 (7.9)
3 1 (1.0) 1 (1.0) 1 (1.0)
Stage method
CT 37 (36.6) 37 (36.6) 37 (36.6)
MRI 64 (63.4) 64 (63.4) 64 (63.4)
T stage*
T1-2 19 (18.8) 26 (25.7) 23 (22.8)
T3-4 82 (81.2) 75 (74.3) 78 (75.2)
N stage*
N0-1 66 (65.3) 46 (45.5) 53 (52.5)
N2-3 35 (34.7) 55 (54.5) 48 (47.5)
Overall stage*
III 50 (49.5) 47 (46.5) 47 (46.5)
IVa-b 51 (50.5) 54 (53.5) 54 (53.5)
RT technique
2D conventional RT 93 (92.1) 94 (93.1) 92 (91.1)
3D conformal RT 1 (1.0) 1 (1.0) 1 (1.0)
IMRT 7 (6.9) 6 (5.9) 8 (7.9)
RT dose (median)
NP 70 70 70
LN 60 62 60
Abbreviations: WHO, World Health Organization; PS, Performance Status; ECOG, Eastern Cooperative Oncology Group; ACE-27, Adult Comorbidity Evaluation-27;
CT, Computed Tomography; MRI, Magnetic Resonance Imaging; RT, Radiotherapy; IMRT, Intensity-Modulated Radiotherapy; NP, Nasopharynx; LN, Lymph node.
*The 7th AJCC/UICC staging system.
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between the groups did not show statistical significance
(4.0% vs. 3.0%, Fisher’s exact test, P=1.000).
Table 3 lists the specifics of chemotherapy in the CRT
and referent group. All patients received concurrent cis-
platin chemotherapy, with 45 (44.6%) and 56 (55.4%) in
the CRT group, and 51 (50.5%) and 50 (49.5%) patients
in the referent group, receiving the 3-weekly and weekly
regimen respectively (P=0.398). The chemotherapy cy-
cles were similar in both groups (P=1.000 for 3-weekly
regimen and P=0.956 for weekly regimen). In the CRT
group, only 31.1% (14/45) of patients received three cy-
cles of 3-weekly regimen. With respect to the weekly
regimen, 58.9% of patients received at least six cycles of
chemotherapy. There were 21 (20.8%) and 4 (4.0%) pa-
tients in the CRT and referent group received decreased
doses of concurrent cisplatin (P<0.001). However, the
median total dose of concurrent cisplatin was the same
in both groups (240 mg/m2 for weekly regimen and
160 mg/m2 for 3-weekly regimen). Altogether, there
were 27 (26.7%) patients in the CRT and referent group
received sequential chemotherapy.
We further analyzed the relationship between chemo-
therapy tolerance and ACE-27 score in the CRT group.
Totally, 21 patients had decreased chemotherapy dose,
and we found 6 of them had ACE-27 score≥2, which
was significant higher than patients with ACE-27
score<2 (54.5% vs. 16.7%, P=0.009).
Toxicity
Incidences of major acute and late toxicities are listed in
Table 4. The toxicities were graded using the Common
Terminology Criteria for Adverse Events (CTCAE) v3.0
[17] or Radiation Therapy Oncology Group/European
Organisation for Research and Treatment of Cancer
(RTOG/EORTC) Late Radiation Morbidity Scoring
Schema [18]. Altogether, 110 (54.5%) patients experi-
enced one or more severe acute toxicities (grade≥3), al-
though no treatment-related death was reported in
either elderly group. However, patients in the CRT group
had a significantly higher rate of any severe toxicities
(65.3% in the CRT group vs. 43.6% in the RT group,
P=0.002). Regarding non-hematologic toxicities, inci-
Table 3 Chemotherapy details
Characteristics CRT group Referent group
NAC (%) N=15 CC (%) N1=45, N2=56 AC (%) N=12 NAC (%) N=15 CC (%) N1=51, N2=50 AC (%) N=12
Cycles
3-weekly regimen
1 8 (53.3) 5 (11.1) 7 (58.3) 6 (40.0) 5 (9.8) 7 (58.3)
2 7 (46.7) 26 (57.8) 5 (41.7) 9 (60.0) 30 (58.8) 5 (41.7)
3 0 (0.0) 14 (31.1) 0 (0.0) 0 (0.0) 16 (31.4) 0 (0.0)
Weekly regimen
5 0 (0) 23 (41.1) 0 (0) 0 (0) 20 (40.0) 0 (0)
6 0 (0) 22 (39.3) 0 (0) 0 (0) 19 (38.0) 0 (0)
7 0 (0) 11 (19.6) 0 (0) 0 (0) 11 (22.0) 0 (0)
Dose modification 3 (20.0) 21 (20.8) 4 (33.3) 2 (13.3) 4 (4.0) 2 (16.7)
Abbreviations: NAC, Neo-adjuvant chemotherapy; CC, Concurrent chemoerapy; AC, Adjuvant chemotherapy.
Table 2 Comorbid grades and affected systems of elderly patients
Body system* N=202 (%) RT alone (N=101) CRT (N=101)
Mild Moderate Severe Mild Moderate Severe
Cardiovascular 36 (17.8) 11 5 1 13 6 0
Respiratory 3 (1.5) 2 0 0 1 0 0
Gastrointestinal 24 (11.9) 13 4 1 5 1 0
Endocrine 13 (6.4) 4 2 1 1 4 1
Neurological 3 (1.5) 0 1 0 1 1 0
Substance abuse 4 (2.0) 1 0 0 3 0 0
Multi-Systems 9 (4.5) 4 2 1 0 2 0
Overall 71 (35.1) 26 10 1 23 10 1
*Abnormality in other systems (renal, psychiatric, rheumatologic, immunological systems and malignancy, body weight) was not found in both groups.
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dences of severe oral mucositis (52.5% vs. 37.6%,
P=0.034) and severe emesis (6.0% vs. 0%, P=0.029) were
significantly higher in the CRT group, while no signifi-
cant difference was detected with regard to the incidence
of severe dermatitis between the groups (12.9% in the
CRT group vs. 7.9% in the RT group, P=0.249). No se-
vere diarrhea and renal toxicity were seen in either
group. Regarding hematologic toxicities, incidences of
severe leukopenia (11.9% vs. 0%, P<0.001), and
granulocytopenia (16.8% vs. 0%, P<0.001) were signifi-
cantly higher in the CRT group. Late toxicities were also
assessed in our study, which involved the following four
conditions: xerostomia, ear problems, subcutaneous fi-
brosis and trismus. In total, the incidence rate of any se-
vere late toxicity was 11.9% (24/202). Unlike with acute
toxicity, the incidence of severe toxicity was comparable
between both groups (10.1% in the CRT group vs. 12.9%
in the RT group, P=0.664). In the referent group, 63
(62.4%) and 18 (17.8%) patients experienced grade≥3
acute and late toxicity, respectively. It is noteworthy that
no significant difference was found in severe toxicity be-
tween the CRT and referent group (P=0.660 for acute
toxicity and P=0.160 for late toxicity).
Table 5 shows the severe toxicity in different ACE-27
scores in elderly patients. We found that the rate of se-
vere acute toxicities was higher in patients with ACE-27
score≥2, but the difference did not reach statistical sig-
nificance (68.2% vs. 52.8%, P=0.171). However, stratified
analysis shows that patients with ACE-27 score≥2 in the
CRT group had significantly higher rate of severe acute
toxicities than patients with ACE-27 score<2 (100% vs.
61.1%, P=0.008), while the difference was not significant
in the RT group (36.4% vs. 44.4%, P=0.752). For late
toxicities, the severe toxicities were similar in different
ACE-27 scores (data not shown).
Clinical response
The tumor response was evaluated by endoscopy and
imaging at 3 months after RT. The complete response
(CR) rate at the primary site was 96.0% (97/101) for el-
derly patients treated with CRT and 95.0% (96/101) for
patients treated with RT alone. Similarly, the CR rate at
the neck area was 93.1% (94/101) for elderly patients
that received CRT and 92.1% (93/101) for patients re-
ceived RT alone. In each elderly group, 90 patients
(89.1%) had a complete response at both the primary site
Table 4 Patients experienced severe (grade 3 or 4) toxicities by treatment group
Toxicity CRT (%, N=101) RT (%, N=101) P
Grade 3 Grade 4 All Grade 3 Grade 4 All
Acute toxicity
Leukopenia 12 (11.9) 0 (0) 12 (11.9) 0 (0) 0 (0) 0 (0) < 0.001
Granulocytopenia 17 (16.8) 0 (0) 17 (16.8) 0 (0) 0 (0) 0 (0) < 0.001
Thrombocytopenia 5 (5.0) 0 (0) 5 (5.0) 0 (0) 0 (0) 0 (0) 0.059
Anemia 6 (5.9) 0 (0) 6 (5.9) 1 (1.0) 0 (0) 1 (1.0) 0.118
Mucositis 52 (51.5) 1 (1.0) 53 (52.5) 38 (37.6) 0 (0) 38 (37.6) 0.034
Dermatitis 13 (12.9) 0 (0) 13 (12.9) 8 (7.9) 0 (0) 8 (7.9) 0.249
Hearing loss 1 (1.0) 0 (0) 1 (1.0) 0 (0) 0 (0) 0 (0) 1.000
Emesis 6 (6.0) 0 (0) 6 (6.0) 0 (0) 0 (0) 0 (0) 0.029
Hepatitis 2 (2.0) 0 (0) 2 (2.0) 2 (2.0) 0 (0) 2 (2.0) 1.000
Total any 65 (64.4) 1 (1.0) 66 (65.3) 44 (43.6) 0 (0) 44 (43.6) 0.002
Late toxicity
Xerostomia 2 (2.0) 0 (0) 2 (2.0) 2 (2.0) 0 (0) 2 (2.0) 1.000
Ear (deafness/otitis) 8 (8.0) 0 (0) 8 (8.0) 9 (8.9) 0 (0) 9 (8.9) 0.800
Subcutaneous Fibrosis 6 (6.0) 0 (0) 6 (6.0) 8 (7.9) 0 (0) 8 (7.9) 0.580
Trismus 3 (3.0) 0 (0) 3 (3.0) 1 (1.0) 0 (0) 1 (1.0) 0.621
Total any 11 (10.1) 0 (0) 11 (10.1) 13 (12.9) 0 (0) 13 (12.9) 0.664
Table 5 Association of severe acute toxicity and ACE-27 score
Acute
toxicity
Overall RT group CRT group
ACE-27≥2 ACE-27<2 P ACE-27≥2 ACE-27<2 P ACE-27≥2 ACE-27<2 P
Grade≥3 15 95 0.171 4 40 0.752 11 55 0.008
Grade<3 7 85 7 50 0 35
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and neck area (P=1.000). For the referent group, the
overall CR rate was 96.0% (97/101), and the CR rate at
the primary site and neck area was 97.0% (98/101) and
98.0% (99/101), respectively. There was no significant
difference in overall CR rate between the CRT and refe-
rent group (P=0.060).
Survival
Our median follow-up period was 67.5 months (range: 8
to 114 months). One hundred and twenty-one deaths
(52 from the CRT group vs. 69 from the RT group) were
detected during the follow-up period, of which 104
(86.0%) were disease-related (44 in the CRT group vs. 57
in the RT group). Other causes of death included comor-
bidity (12 patients), old age (3 patients) and accidents
(2 patients). The 5-year OS in the CRT group was 54.6%
compared with 39.3% in the RT group (P=0.009,
Figure 2A), with a hazard ratio of 0.619 (95% CI, 0.430-
0.890; P=0.009). Thus, CRT decreased nearly 40% death
risk in elderly locoregionally advanced NPC patients.
Patients in the CRT group also had significantly higher
5-year CSS than did patients in the RT group (56.6% vs.
42.7%, P=0.022, Figure 2B). In the referent group, the
5-year OS and CSS were significantly higher than the
CRT group (75.3% vs. 54.6%, P<0.001 and 77.8% vs.
56.6% P<0.001).
Patterns of treatment failure
In total, 120 (59.4%) patients displayed progressed di-
sease after treatment, among which 53 and 67 patients
were from the CRT and RT groups, respectively. The
5-year DFS of the CRT group was higher than that of
the RT group (51.6% vs. 30.2%, P=0.028, Figure 2C). Dis-
tant metastasis was common in our study. Altogether,
28.2% (57/202) of patients developed distant metastasis
(28 and 29 patients in the CRT and RT groups, respec-
tively). The 5-year DMFS was similar for both groups
(69.6% in the CRT group vs. 63.6% in the RT group,
P=0.669, Figure 2D). A total of 63 patients had local
and/or regional relapse, among whom 22 and 41 patients
were from the CRT and RT groups, respectively. Of note,
patients from the CRT group had a significantly higher
5-year LRRFS (78.4% vs. 52.2%, P=0.003, Figure 2E). The
5-year DFS, and LRRFS were significantly higher in the
referent group than the CRT group (68.2% vs. 51.6%,
P=0.001 and 88.4% vs. 78.4%, P=0.017), but the diffe-
rence in 5-year DMFS was not significant between both
groups (78.2% vs. 69.6%, P=0.128).
Efficacy in patients with severe comorbid status
We separated all elderly patients into two groups
according to their comorbidity status (ACE-27 scores of
0–1 vs. 2–3). Based on a previous study that showed
Figure 2 Kaplan-Meier estimates of the survival of elderly locoregionally advanced nasopharyngeal carcinoma patients, by treatment
group (CRT vs. RT). (A) overall survival; (B) cancer-specific survival; (C) disease-free survival; (D) distant metastasis-free survival; and
(E) locoregional relapse-free survival.
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that elderly NPC patients with ACE-27 scores of 2–3
had poorer 5-year OS and CSS [10], we selected patients
with severe comorbidity (ACE-27 scores of 2–3) to fur-
ther explore the efficacy of CRT in this cohort.
Altogether, there were only 11 patients in each group.
It is noteworthy that CRT did not improve either OS or
CSS in these patients (5-year OS of 43.6% in the CRT
group vs. 27.3% in the RT group, P=0.893, Figure 3A;
5-year CSS of 43.6% in the CRT group vs. 34.1% in the
RT group, P=0.971; Figure 3B).
Discussion
Three previous meta-analyses have confirmed that the
addition of chemotherapy to radiotherapy could signifi-
cantly improve survival in locoregionally advanced NPC
patient, with concurrent chemotherapy displaying the
largest effect [19-21]. Therefore, the National Comprehen-
sive Cancer Network (NCCN) guidelines recommend con-
current CRT with adjuvant chemotherapy as the standard
regimen for locoregionally advanced NPC patients. How-
ever, because elderly NPC patients who meet the strict se-
lection criteria accounted for only a small part of these
studies, the real role of chemotherapy in this population is
still unclear. Our matched cohort analysis aimed to clarify
the feasibility and efficacy of CRT among elderly loco-
regionally advanced NPC patients.
Combined chemotherapy and radiotherapy seemed to
be less acceptable in the elderly NPC patients. Our data
showed that many patients could not tolerate the full cy-
cles of chemotherapy, with several patients experiencing
dose modifications due to severe gastrointestinal reac-
tions, suppressed bone marrow function and subjective
denial. Regarding concurrent chemotherapy, only 31.1%
of patients finished three cycles of high dose cisplatin,
which was much lower than other published clinical tri-
als (52%-71%) [2,7,22]. However, a weekly cisplatin regi-
men seemed to be much more tolerable, with 58.9% of
patients completing at least 6 cycles in our study. Al-
though, this result was lower than our previous phase III
trial for stage II NPC patients (78.4%) [23], it is higher
than those published by Chan et al. [24], which showed
that only 44% of patients could tolerate at least 6 cycles
of weekly cisplatin. According to clinical trials published
to date, there have not been clear differences between
the 3-weekly and weekly concurrent regimens of cis-
platin in NPC. In present study, we found that the me-
dian total cisplatin dose in concurrent phase of weekly
regimen was higher than that of 3-weekly regimen
(240 mg/m2 vs. 160 mg/m2) in elderly patients. There-
fore, the weekly concurrent regimen might be more ap-
propriate for them.
The rates of severe acute and late toxicities in our study
were similar to those of previously published clinical trials
[2,5-7,23], and also we found that rates of severe toxicities
caused by CRT in elderly patients were similar with young
patients. A recent article that investigated multi-agent
concurrent CRT for locally advanced head and neck squa-
mous cell cancers in the elderly also found that toxicities
were similar between the elderly and younger populations,
although the elderly experienced more myelosuppression,
required more unplanned hospitalization, and needed lon-
ger time with the feeding tube [25]. Furthermore, in our
study, toxicities in both groups were manageable, with no
incidence of treatment-related death and only a few cases
of radiotherapy interruption. Therefore, combined CRT
may be feasible in the elderly NPC population. We also
found patients with severe comorbid status (ACE-27 score
of 2–3) were related with significantly higher rate of severe
acute toxicity in CRT group, but not in RT alone group.
This is confirmed by previous review which showed
Figure 3 Kaplan-Meier estimates of the survival of elderly
locoregionally advanced nasopharyngeal carcinoma patients with
severe comorbidities (ACE-27 score of 2–3), by treatment group
(CRT vs. RT). (A) overall survival and (B) cancer-specific survival.
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comorbidity was related with higher grade 3 to 4 toxicity
induced by chemotherapy [8].
Compared to other large clinical trials (which involved
only a few elderly patients), the elderly patients in our
study seemed to have poorer survival. The 5-year OS of
the CRT and RT groups was 67% vs. 37% in the
Intergroup Study 0099 [26]; 68% vs. 64% in the Hong
Kong 9901 trial [5]; and 70.3% vs. 56.8% in another trial
from Hong Kong [27], respectively. However, our results
were 54.6% vs. 39.3%, respectively. With respect to
5-year CSS, the results in our study were also lower than
theirs. Results were similar when the CRT group com-
pared with the referent group. Previous studies have also
reported poor treatment outcomes in elderly NPC pa-
tients [10,28,29]. Decreased body function, higher rates
of co-existing comorbidities and inadequate tolerability
for chemotherapy were potential reasons for the rela-
tively poor treatment outcomes.
A meta-analysis that included 93 randomized trials
and 17,246 head and neck patients (without any NPC
patients) found that, although the addition of chemo-
therapy for locoregional treatment could significantly
improve survival, the efficacy of chemotherapy decreased
with increasing age (test for trend, P=0.003). The same
report ascribed this phenomenon to the increased pro-
portion of death not due to head and neck cancers with
age (15% in patients younger than 50 years vs. 39% in
patients 71 years and older) [30]. However, a subsequent
retrospective study showed controversial results. Com-
pared to patients<70 years, patients≥70 years with locally
advanced head and neck squamous cell cancers treated
with multi-agent concurrent CRT had nearly identical
projected 5-year disease-specific survival (74% vs. 71%)
and freedom from recurrence (71% vs. 69%) [25]. Re-
garding NPC, a meta-analysis of eight randomized trials
and 1,753 locally advanced NPC patients detected no
significant interactions between the treatment effect and
age [20]. However, this analysis separated all patients
into only three age groups (<41, 41–50 and ≥51), with-
out exact numbers of elderly patients. Ho et al. used
modified weekly cisplatin (30 mg/m2) as concurrent
regimen in elderly NPC patients and still showed favor-
able 2-year survival, with OS, DFS, LRRFS and DMFS
observed at 87%, 73%, 92% and 76%, respectively [31],
but their sample was relatively small (26 patients could
be analyzed) and it took patients aged lower than
65 years into analysis. In our study, we found that CRT
could still significantly improve 5-year OS, CSS, DFS
and LRRFS but not DMFS when compared to RT alone
in elderly NPC patients. It is obvious that the benefits
in OS and CSS were mainly derived from a higher
locoregional control in the CRT group. Therefore, CRT
is still important for elderly locoregionally advanced
NPC patients.
However, CRT was not effective in all elderly patients.
Our stratified study showed that CRT could not signifi-
cantly improve either the 5-year OS or CSS in elderly
NPC patients with severe comorbidities (ACE-27 scores
of 2–3). Over 50% patients (ACE-27 score≥2) had dose
reduction in the CRT group could be one of the impor-
tant reason. A systemic review also showed that comor-
bidity was related to decreased chemotherapy use,
tolerability and inferior survival in various cancers [8].
Considering the worse tolerance, higher severe acute
toxicity and no significant survival benefit, using CRT in
elderly NPC patients with severe comorbidity should be
under serious consideration.
There are some limitations to this study. First of all,
this is a retrospective study; secondly, our stratified
study had a small sample; then, no quality of life data in
this study; at last most of our patients were treated with
2D conventional RT, while the widely using of IMRT
showed excellent locoregional control in NPC. There-
fore, further prospective randomized trials with large
sample should be conducted to test CRT in elderly NPC
patients treated with IMRT.
Conclusions
In conclusion, to the best of our knowledge, our study is
the first one which directly compared CRT and RT alone
in elderly NPC patients to explore feasibility and efficacy
of CRT in them. We found that CRT was feasible and
effective in elderly patients with locoregionally advanced
NPC without severe comorbidities. CRT should be used
under serious consideration and be further tested in el-
derly patients with severe comorbidities. As such, it is
essential to perform a comprehensive evaluation of pre-
treatment comorbidity status for all elderly patients with
NPC.
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